Cantargia AB (CHIX:CANTAS) 3-Year Share Buyback Ratio: -14.20% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CANTAS Cantargia AB CHIX:CANTAS
33 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB 3-Year Share Buyback Ratio?

Cantargia AB CHIX:CANTAS 33 3-Year Share Buyback Ratio is -14.20 as of Jun. 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,190 Biotechnology companies, Cantargia AB ranks worse than 55.21% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cantargia AB's current 3-Year Share Buyback Ratio was -14.20%.

The historical rank and industry rank for Cantargia AB's 3-Year Share Buyback Ratio or its related term are showing as below:

CHIX:CANTAs' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -80   Med: -22.6   Max: 0
Current: -14.2

During the past 13 years, Cantargia AB's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -80.00%. And the median was -22.60%.

CHIX:CANTAs's 3-Year Share Buyback Ratio is ranked worse than
55.21% of 1190 companies
in the Biotechnology industry
Industry Median: -11.75 vs CHIX:CANTAs: -14.20

Cantargia AB (CHIX:CANTAs) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Cantargia AB 3-Year Share Buyback Ratio Related Terms


CHIX:CANTAS vs VRTX, REGN, RVMD: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Cantargia AB's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Cantargia AB's 3-Year Share Buyback Ratio falls into.


CHIX:CANTAS
33GF Score
Cantargia AB CHIX:CANTAS
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -14.20 mean?
Cantargia AB (CHIX:CANTAS) has a 3-Year Share Buyback Ratio of -14.20 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cantargia AB and its competitors. According to the industry distribution chart, Cantargia AB ranks #657 out of 1190 companies in the Biotechnology industry, placing it in the top 55.2%.
Is Cantargia AB's 3-Year Share Buyback Ratio too high?
Cantargia AB's current 3-Year Share Buyback Ratio is -14.20. Based on the distribution chart, Cantargia AB ranks #657 out of 1190 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cantargia AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #657 out of 1190 companies for 3-Year Share Buyback Ratio. This places Cantargia AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cantargia AB and its competitors. Cantargia AB's current 3-Year Share Buyback Ratio is -14.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current 3-Year Share Buyback Ratio of -14.20. The current 3-Year Share Buyback Ratio is -14.20. Cantargia AB's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current 3-Year Share Buyback Ratio is -14.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
33GF Score

Get the complete analysis for CHIX:CANTAS

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price